Tumor Cells as Architects of Immune Refractoriness: Dismantling Intrinsic Programs of Tumor Cells for Clinical Translation.

T cell-based immunotherapies have transformed cancer treatment, yet only a minority of patients achieve durable remission because tumors display primary or acquired resistance. While most frameworks attribute therapeutic failure to impaired T-cell activity or immunosuppressive tumor microenvironment (TME), growing evidence indicates that a deeper layer of refractoriness originates within tumor cells themselves. Oncogenic mutations endow tumor cells with survival, and immune-evasive programs, establishing a molecular foundation for multi-malignant and immune-refractory behavior. Under sustained immune pressure and crosstalk with stromal and immune components, these programs are reinforced through epigenetic remodeling and hyperactivation of oncogenic signaling. Importantly, tumor cell-encoded programs extend beyond the cell, orchestrating fibroblast activation, abnormal angiogenesis, suppressed Ag presentation, and recruiting suppressive immune subsets. In this way, tumor cells construct a microenvironment that perpetuates their own resistant state. This review proposes a paradigm shift from an immune-centric to a tumor cell-centric framework, arguing that durable therapeutic control will require dismantling the regulatory networks within tumor cells that couple oncogenesis with immune evasion. By decoding how tumor cells establish and stabilize multilayered immune refractoriness, we outline strategies to identify actionable vulnerabilities and design next-generation therapies that reprogram tumor cells and recondition the TME toward sustained anti-tumor immunity.